Cargando…
Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy
Immune checkpoint inhibitors (ICIs) have revealed significant clinical values in different solid tumors and hematological malignancy, changing the landscape for the treatment of multiple types of cancer. However, only a subpopulation of patients has obvious tumor response and long-term survival afte...
Autores principales: | Zheng, Lin-Peng, Yang, Jing, Chen, Xie-Wan, Li, Ling-Chen, Sun, Jian-Guo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126660/ https://www.ncbi.nlm.nih.gov/pubmed/37113734 http://dx.doi.org/10.1177/17588359231163807 |
Ejemplares similares
-
Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022) -
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
por: Bai, Yuezong, et al.
Publicado: (2022) -
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020) -
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
por: Posner, Atara, et al.
Publicado: (2023) -
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)